Pipeline

Oryzon Genomics is a clinical stage biopharmaceutical company that discovers, develops, and plans to commercialize novel epigenetic therapies to treat oncological/hematological disorders and CNS diseases.

Our therapeutic strategy is to treat the underlying causes of these diseases by targeting lysine specific demethylase 1 (LSD1, also known as KDM1A). LSD1 is a histone modifying enzyme that is involved in the regulation of the expression of many genes important in the onset and progression of human diseases such as cancer and CNS disorders.

As reflected in the chart below, Oryzon has two drugs in clinical development in multiple therapeutic indications: iadademstat, a selective LSD1 inhibitor for oncology/hematology, and vafidemstat, a CNS optimized LSD1 inhibitor for CNS and psychiatric disorders. Our pipeline also includes ORY-4001, a selective HDAC6 inhibitor, and additional programs at earlier stages of development.